Compare Ascendis Pharma A/S (ASND) vs Atomera Incorporated (ATOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Atomera Incorporated — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Atomera Incorporated trades at $6.69 (market cap $256.50M). The key difference: Ascendis Pharma A/S is far larger — about 69.2× Atomera Incorporated's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Atomera Incorporated nearer its low. Which is the better fit depends on your goals.
| ASND | ATOM | |
|---|---|---|
Market Cap | $17.74B | $256.50M |
Sector | Health | Technology |
52-Week High | $277.18 | $12.11 |
52-Week Low | $163.32 | $1.99 |
Enterprise Value | $18.11B | $216.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ATOM trades at $6.63, down 2.93% with bearish technical signals. The company shows severe financial strain with negative gross profit margin of -520.83% and net income margin of -29,219.44% for 2025. Recent earnings misses and negative cash flow highlight operational challenges, though analyst consensus remains 100% buy rating based on technology licensing potential in semiconductor materials.
Outlook remains speculative with significant execution risk. The company's GaN-on-Silicon technology partnerships with Synopsys offer potential upside, but current financial metrics and consistent losses warrant caution. Investment opportunity exists only for risk-tolerant investors betting on technology adoption breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Atomera Incorporated
Atomera is a semiconductor materials engineering company. Its Mears Silicon Technology (MST) is a patented thin film that enhances transistor performance, power efficiency, and cost for global chip manufacturers.
Read more on ATOM →
